Microenvironment drug resistance in multiple myeloma: emerging new players.
Microenvironment drug resistance in multiple myeloma: emerging new players.
复制标题
DOI：
10.18632/oncotarget.10849
复制
发表时间：
2016-09-13
期刊：
影响因子：
--
通讯作者：
Frassanito MA
中科院分区：
文献类型：
--
作者：
Di Marzo L;Desantis V;Solimando AG;Ruggieri S;Annese T;Nico B;Fumarulo R;Vacca A;Frassanito MA
多发性骨髓瘤(MM)耐药(DR)是一个多步骤的转化过程，基于骨髓基质细胞和MM细胞之间的强大相互作用，使后者能够逃避抗骨髓瘤治疗。在此，我们综述了骨髓微环境在可溶性因子介导的耐药(SFM-DR)和细胞黏附介导的耐药(CAM-DR)中的作用，重点介绍了新的参与者，即miRNAs、外切体和癌症相关成纤维细胞的作用。
Multiple myeloma (MM) drug resistance (DR) is a multistep transformation process based on a powerful interplay between bone marrow stromal cells and MM cells that allows the latter to escape anti-myeloma therapies. Here we present an overview of the role of the bone marrow microenvironment in both soluble factors-mediated drug resistance (SFM-DR) and cell adhesion-mediated drug resistance (CAM-DR), focusing on the role of new players, namely miRNAs, exosomes and cancer-associated fibroblasts.